Catalyst Edge · Scanner · Tickers · LLY
CATALYST DOSSIER · UPDATED 2026-11-03

$LLY

pharma · convergence 2 · conviction WATCH
Convergence Score
2
Conviction
WATCH
Signals Firing
9
Track Record
2/2
Quick tools:🃏 Swipe deck🎯 Today verdict

Price & Live Quote

Loading live quote & chart…

Practice trade tools

Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.

Paper trade unavailable: missing risk-bounded frame

Reference only. Not financial advice. No brokerage order is placed.

Why $LLY?

LLY 2 WATCH pharma

Quantitative

  • Revenue (CY2026Q2): $22.97B (+47.7% YoY)
  • Net Income (CY2026Q2): $7.09B (+25.3% YoY)
  • Net Margin (CY2026Q3): 26.4%

Catalysts

  • Clinical trial milestone: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
  • New insider (Form 3): 1 new beneficial owner filing(s) — institutional accumulation signal 2026-10-22

Risks

  • Position-sizing discipline: Conviction WATCH (2 score) — size accordingly; no specific catalyst-fade risk flagged

Bear case

  • Multiple compression: If breadth deteriorates, pharma-wide multiples re-rate lower regardless of pick-specific thesis

Sympathy basket (cerebro)

  • AMGN via pharma r=+0.00 intra-sector (score 25)
  • PFE via pharma r=+0.00 intra-sector (score 20)
  • BMY via pharma r=+0.00 intra-sector (score 11)
  • ABBV via pharma r=+0.00 intra-sector (score 10)
  • IBB via pharma r=+0.00 intra-sector (score 8)
  • XBI via pharma r=+0.00 intra-sector (score 8)

Signals Firing

clinicalfda_appmacroorphan_leanoge_execauto_macro_adp_payrollsauto_macro_durable_goodsauto_macro_fx_ratesauto_macro_treasury_fiscal
Each tag is a spoke that flagged this ticker today. Weights tuned weekly against published outcomes.

Pick Track Record

DateListNext-day max runNext-day closeHit +2%?
2026-10-29sec_top_gappers+5.5%+3.2%✓ hit
2026-10-29sec_top_moat_emerging+5.5%+3.2%✓ hit
Lifetime: 2/2 wins · hit-rate 100.0% on +2% intraday

Sympathy Basket

Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.

Earnings Catalyst

No recent earnings event.

Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology. Not financial advice. Confirm independently before trading.

You came here for LLY. You found it after it moved, the same way everyone else did.

$99 once — every ticker on this site ranked before the open.

Tier 1 setups touched +2% intraday 44.0% of the time across 414 tracked calls. Baseline for everything else: 38.4%. That is a +5.6 point edge, measured from the NEXT OPEN — the first price you could actually pay, not the prior close. We publish the misses too: https://catalystedgescanner.com/trust/

  1. Click Become a Founding Member below.
  2. Pay $99 once — not monthly, not ever again.
  3. You keep every future release at that price. Tomorrow's ranked list lands at 3:30 AM ET, before the open.

30 of 30 founding seats left. The price goes up when they are gone.

Become a Founding Member — $99 once

One payment, access for as long as we run the service. The free daily picks stay free — this is for people who want the full console. Not buying today? Get tomorrow's ranked list free →